Healthcare Intelligence
Pharma Commercialization & Sales
Real-time intelligence, expert analysis, and verified research for the Pharma Commercialization & Sales industry. Stay ahead in 3 minutes a day.
Stay ahead of Pharma Commercialization & Sales in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Lilly's Next-Gen Obesity Drug Achieves 28% Weight Loss in Trial
Retatrutide helped patients lose 28.3% body weight over 80 weeks, potentially becoming the most powerful weight-loss drug on market.
Read full articleOral Weight-Loss Pills Draw Patients From Compounded GLP-1 Drugs
Lower-cost oral obesity drugs from Novo and Lilly are shifting patients away from compounded therapies as branded options expand access.
Read full articleBiotechs Run Covert Campaign to Oust FDA Commissioner Makary
Exclusive report reveals organized effort by biotech companies to push out FDA Commissioner Marty Makary over regulatory disputes.
Read full articleAmgen CFO Peter Griffith to Retire; Thomas Dittrich Named Successor
Griffith becomes second high-profile exec to leave Amgen in 2026, retiring Sept 1 as company faces pressure over Tavneos safety concerns.
Read full articleChina Launches Major Crackdown on Pharma Kickbacks
New regulations effective Aug 1 redefine drug reps as academic promoters, ban sales quotas and require national registration of 116,000 reps.
Read full articleLilly's Next-Gen Obesity Drug Achieves 28% Weight Loss in Trial
Retatrutide helped patients lose 28.3% body weight over 80 weeks, potentially becoming the most powerful weight-loss drug on market.
Read full articleOral Weight-Loss Pills Draw Patients From Compounded GLP-1 Drugs
Lower-cost oral obesity drugs from Novo and Lilly are shifting patients away from compounded therapies as branded options expand access.
Read full articleBiotechs Run Covert Campaign to Oust FDA Commissioner Makary
Exclusive report reveals organized effort by biotech companies to push out FDA Commissioner Marty Makary over regulatory disputes.
Read full articleAmgen CFO Peter Griffith to Retire; Thomas Dittrich Named Successor
Griffith becomes second high-profile exec to leave Amgen in 2026, retiring Sept 1 as company faces pressure over Tavneos safety concerns.
Read full articleChina Launches Major Crackdown on Pharma Kickbacks
New regulations effective Aug 1 redefine drug reps as academic promoters, ban sales quotas and require national registration of 116,000 reps.
Read full articleStay ahead of Pharma Commercialization & Sales in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.